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a  b  s  t  r  a  c  t
Funded  immunization  programs  are  best  able  to  achieve  high  participation  rates,  optimal  protection  of
the  target  population,  and  indirect  protection  of others.  However,  in  many  countries  public  funding  of
approved  vaccines  can  be substantially  delayed,  limited  to  a  portion  of the  at-risk  population  or  denied
altogether.  In these  situations,  unfunded  vaccines  are  often  inaccessible  to  individuals  at  risk,  allowing
potentially  avoidable  morbidity  and  mortality  to  continue  to  occur.  We  contend  that  private  access  to
approved  but  unfunded  vaccines  should  be  reconsidered  and  encouraged,  with  recognition  that  individ-
uals  have  a prerogative  to  take  advantage  of  a vaccine  of  potential  beneﬁt  to  them  whether  it is  publicly
funded  or  not.  Moreover,  numbers  of  “approved  but  unfunded”  vaccines  are  likely  to grow  because  gov-
ernments  will  not  be  able  to fund  all future  vaccines  of  potential  beneﬁt  to  some  citizens.  New  strategies
are  needed  to better  use unfunded  vaccines  even  though  the  net  beneﬁts  will  fall  short  of  those  of funded
programs.
Canada,  after  recent  delays  funding  several  new  vaccine  programs,  has  developed  means  to  encourage
private  vaccine  use.  Physicians  are  required  to  inform  relevant  patients  about  risks and  beneﬁts  of  all  rec-
ommended  vaccines,  publicly  funded  or  not.  Likewise,  some  provincial  public  health  departments  now
recommend  and  promote  both  funded  and  unfunded  vaccines.  Pharmacists  are  key players  in making
unfunded  vaccines  locally  available.  Professional  organizations  are  contributing  to  public  and  provider
education  about  unfunded  vaccines  (e.g.  herpes  zoster,  not  funded  in any  province).  Vaccine  companies
are  gaining  expertise  with  direct-to-consumer  advertising.  However,  major  challenges  remain,  such  as
making  unfunded  vaccines  more  available  to  low-income  families  and  overcoming  public  expectations
that  all  vaccines  will  be provided  cost-free,  when  many  other  recommended  personal  preventive  meas-
ures  are  user-pay.  The  greatest  need  is  to  change  the  widespread  perception  that  approved  vaccines
 or  ig
 201should  be  publicly  funded
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During the past decade an unprecedented number of important
ew vaccines were approved for use in economically advantaged
ountries but subsequent population access was seldom speed-
ly achieved. The process by which new vaccines gain approval
nd ultimately reach consumers is increasingly complex as vac-
ine technology advances and costs increase. The approval process
egins with in-depth review of vaccine properties and performance
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by the national biologics regulator, the successful conclusion of
which is marketing authorization (or licensure in some countries).
In theory, vaccine consumption can begin at this point. However,
vaccines are best provided to populations through funded public
programs, consideration of which requires additional review, usu-
ally by the national immunization technical advisory group (NITAG)
[1]. These experts consider the broader public health implications
of vaccine use including local disease epidemiology, program feasi-
bility, cost-effectiveness, potential herd immunity, equity of access,
and other issues, sometimes using a formal analytical framework
[1,2] to reach a recommendation for population use. The ﬁnal step
towards a public program is funding approval, often involving
other government departments with competing funding requests
Open access under CC BY-NC-SA license.impinging on the process. Whereas requests to fund vaccines are
increasingly framed in economic terms, equally stringent criteria
are seldom applied to other major healthcare expenditures, such
as new therapeutic agents.
 license.
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An unfortunately common consequence of this multi-step pro-
ess is delayed population access to an approved vaccine. A recent
tudy of European countries [3] showed that the median interval
etween marketing authorization and population access to three
ewer vaccines (if granted) was 6.5 years, with wide variation
mong countries. Prolonged NITAG deliberations were the major
ource of delay.
A  number of other circumstances can limit population access to a
ew vaccine. Countries may  reach different conclusions about vac-
ine use, with some supplying it to their population and others not.
or example, varicella vaccination programs receive public funding
n the USA, Canada, and Australia but not in the United Kingdom;
owever, the UK funds zoster vaccine for seniors [4] while the
ther countries mentioned do not. The UK’s NITAG [5] recently
ecided not to recommend funding a new vaccine against group
 meningococcal infection (MenB), citing mainly inadequate cost-
ffectiveness, a decision decried by some as ﬂawed [6,7]. Countries
ith multiple independent health jurisdictions can have discordant
nternal programs that depart from the national recommendation.
ustralia provides an example, where one of seven states provides
nﬂuenza vaccine to healthy young children [8]. Population access
o a new vaccine is also inﬂuenced by program scope and whether
 catch-up component is included. Provision of inﬂuenza vaccine
o healthy children in the UK is illustrative: currently 2 and 3 year
lds are eligible and ultimately all children 2–16 years of age will
e eligible [9]. Meanwhile, a few areas of the country are already
xtending vaccinations to older children. Such discrepancies in
opulation access may  be of concern for parents whose children
re at risk but not presently eligible for particular vaccines.
A  question that is too seldom asked is why should individ-
als who could be protected by a newly approved vaccine not
ake advantage of it, whether it is publicly-funded or not? MenB
accine is a case in point since the UK decision against funding
5] inevitably means that some unvaccinated children will die or
uffer permanent harm [6,7]. When public funding of nationally
ecommended or approved vaccines is delayed, limited, or denied,
ndividual protection through vaccination is often inaccessible to
ersons at risk for lack of alternatives such as private sales or aware-
ess thereof. Potentially avoidable morbidity and mortality will
ontinue to occur. It is timely to consider alternatives to all-or-none
ublic access to new vaccines. Should an individual’s prerogative
o take advantage of an approved vaccine not be recognized and
ncouraged, even in the absence of publicly-funded programs? If
o, how might this be accomplished?
Canada  has had recent experience with a number of “rec-
mmended but unfunded vaccines” (RUVs) and is beginning to
ecognize an obligation to facilitate vaccine use outside of public
rograms. Placement of a newly licensed product in the RUV cate-
ory has doomed some previous vaccines to limited uptake [10–12],
ut improvements may  be possible with supportive social changes.
his review shares Canadian experiences with RUVs and offers sug-
estions that might have broad application for increasing public
ccess to unfunded vaccines.
.  Recommended but unfunded vaccines in Canada
Canada has historically been a world leader in quickly adding
ew vaccines to public programs [13–15], but recently, delays
f several years have occurred between marketing authorization
nd public funding of 6 new vaccines. These included pneumo-
occal and meningococcal conjugates, varicella, zoster, Tdap, and
otavirus vaccines. Canada resembles Europe in microcosm: while
e have a single regulatory authority and central NITAGs [16],
ach of the 13 provinces and territories that make up the coun-
ry is individually responsible for immunization program fundinge 32 (2014) 766– 770 767
and  scope. Consequently, vaccines can be supplied to the public
in some provinces but not others, for varying periods of time. For
example, pneumococcal and meningococcal C conjugate vaccines
were approved for sale in 2001 but were not supplied to children
in all provinces until 2005–2006. Rotavirus vaccines were ﬁrst rec-
ommended by the NITAG in 2008 [17] but only 5 of 10 provinces
currently offer funded programs. Zoster vaccine was recommended
by the NITAG in 2010 [18] but no province currently supplies it to
seniors without cost. Furthermore, there appears to be no move-
ment towards public funding of zoster vaccine, tied to the broader
challenges of prioritizing and delivering immunizations for adults.
The RUV category is expected to grow as more vaccines are mar-
keted for adults, including alternative formulations of inﬂuenza
vaccines for seniors. Variability also exists in the scope of funded
provincial programs, which often target only a portion of potential
beneﬁciaries, without a catch-up program for others at risk. Human
papillomavirus (HPV) vaccines are currently used in limited-scope
programs that differ among provinces, with only a subset provid-
ing catch-up programs for older girls/women or targeting boys, as
recommended in 2012 [19].
Thus a recommendation from Canada’s NITAG to use a new
vaccine is no longer synonymous with provision of the vaccine in
publicly-funded programs, as it once was. A recommendation from
the primary NITAG (National Advisory Committee on Immuniza-
tion, NACI) endorses the safety and usefulness of a new vaccine
to protect individuals at risk from infection [16]. Importantly, this
NITAG does not address the additional considerations relevant to
public health for population use. Currently, a second NITAG (Cana-
dian Immunization Committee) [20] representing all provinces and
territories uses a standard analytical framework [2] to examine
the population health beneﬁts that would support public funding
of a new vaccine program. However, recommendations from this
second-level committee have sometimes been much delayed, sim-
ilar to the situation in Europe [3]. While the evidence supporting
routine vaccine use should be equally compelling for each province,
the ability and willingness to pay often differ among them. Even
when provincial public health ofﬁcials favor the introduction of a
new vaccine program, funding decisions ultimately rest with min-
istries of ﬁnance, which face many competing priorities.
While health system administrators may  contend that delays
and limitations in funding public immunization programs reﬂect
“due diligence”, the opportunities lost to improve health and avoid
morbidity and mortality that result from this approach deserve
greater attention. The existence of recommended but unfunded
vaccines was a new phenomenon for which the medical commu-
nity was  unprepared and resulted in the unfunded vaccines being
largely ignored and inaccessible for a time.
2. Recent experiences with RUVs in Canada
2.1. Role of physicians
In  2002, a different perspective began to emerge about RUVs.
The Canadian Medical Protective Association (CMPA, the nation’s
major medical malpractice insurer) recognized the potential
for physician liability if patients in their practice suffered from
infections that could have been prevented by RUVs. CMPA advised
physicians to inform patients about all recommended vaccines
they could beneﬁt from if they choose to pay [21]. There were
objections from some physicians about the extra time required
to mention RUVs, when many were already ﬁnding it difﬁcult to
adequately discuss funded vaccines in the busy ofﬁce setting. There
were also practical difﬁculties with community access to such
vaccines given limited demand. The ability to pay was  limited for
many families and awkward to discuss. Nevertheless, the insurer
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emained insistent on this best practice, which has gradually
ecome easier for physicians to meet as other stakeholders have
oined the initiative (outlined below).
.2. Role of pharmacists
As  demand increased for private vaccine sales, community phar-
acies were more willing to stock and dispense RUVs. In a growing
umber of provinces, pharmacists can qualify to administer as well
s dispense certain vaccines, including RUVs [22]. We  believe this
o be an important trend in Canada and elsewhere [23] as it will
elp to increase the uptake of both funded and unfunded vaccines,
articularly for adults, given the ease of visiting the local phar-
acy even in small communities. Pharmacies are the main source
f self-pay zoster vaccine presently across the country. Having this
third source” of vaccines and vaccinators will assist public health
o rapidly deliver vaccines in the event of an epidemic. The same
nfrastructure will be very helpful for expanding RUV use as phar-
acists and physicians are natural partners. Physicians ﬁnd it easier
o mention RUVs to appropriate patients knowing the local phar-
acist will then help patients make informed decisions, and will
eal with vaccine administration, inventory and, payment.
.3.  Role of public health
The  role played by public health in Canada in delivering
mmunizations  varies among the provinces, some having mainly
hysician-delivered and others mainly public health-delivered pro-
rams. Until recently, public health authorities overseeing both
inds of programs did not consider that they had an obligation to
romote or provide RUVs. While consistent with a narrow inter-
retation of public health’s mandate to provide evidence-based
nterventions of proven public health beneﬁt, this may  be short-
ighted given that most nationally recommended vaccines have
ventually been funded for public programs. Furthermore, the pub-
ic will not be aware of nuances of individual versus population
eneﬁts and governments will not be able to fund every new
accine that offers proven health beneﬁts to some citizens. The pre-
autionary principle, taken to its extremes in other public health
ssues, might also be applied to RUVs since their contribution to
isk reduction may  well outweigh other costly activities of health
epartments, such as contact tracing after large exposure events.
he ﬁnal public health concern is about equity and the opportu-
ity cost of promoting a self-pay intervention that only some can
fford, usually those at lowest risk, and thereby forgoing other
ctivities directed at the most vulnerable. This latter argument is
ountered by the need to be transparent in dealing with the public,
he opportunity to use RUVs to promote the beneﬁts of vaccines
ore generally, and the beneﬁts of learning more about new vac-
ines through their use in the ﬁeld.
Presently public health agencies in several provinces recognize
hat an obligation exists to support the use of all NITAG-
ecommended vaccines, not just the ones their province has chosen
o supply for free [24,25]. These health departments provide similar
romotional materials for funded and unfunded vaccines, directed
t physicians and the public. They also accept the same obligation
hysicians have to mention the availability and potential beneﬁts
f RUVs to appropriate individuals, as best practice. Local clinics
ometimes supply RUVs if other sources are limited, akin to travel
accines. Such a holistic attitude about new vaccines encourages
reater use of these vaccines before they move from RUV limbo to
he funded category and facilitates extension of vaccine use beyond
arrow, funded categories. With RUVs likely here to stay, we hope
hat this enlightened approach will become the norm for all public
ealth departments across the country.e 32 (2014) 766– 770
2.4.  Role of professional organizations
Professional organizations can play key roles in advocating
for the use of RUVs as the public generally values expert advice
that is independent of governments and industry. The Canadian
Paediatric Society [26] is a prominent advocate for use of new
pediatric vaccines (funded and unfunded) and provides helpful
educational materials [27] to physicians and parents, sometimes
as the only non-industry source. Immunize Canada [28], a con-
sortium of professional organizations led by the Canadian Public
Health Association, is increasingly active in providing online and
other education materials for consumers and providers of RUVs
[29]. With more RUVs directed at special populations such as the
elderly or pregnant women, additional professional organizations
should become involved to support their members in advocat-
ing for vaccinations in these unfamiliar settings. Involvement of
Canadian gynecologists was  helpful in promoting use of human
papillomavirus vaccines [30], within and beyond the populations
eligible for free vaccination, and their obstetrician counterparts will
be helpful in advocating for immunizations during pregnancy.
2.5.  Role of vaccine manufacturers
Commercial  promotion of vaccines in Canada is limited because
the purchasers are usually the provincial authorities rather than
individual physicians or patients. Promotional activities are mainly
directed at health professionals through print advertisements, with
ofﬁce “detailing” visits being rare. Print ads have to follow strict
federal content regulations with emphasis on the NITAG recom-
mendations and approved prescribing information. Educational
materials are often developed by manufacturers for use by health
professionals in counseling patients or parents about vaccines but
the messages are understandably not as readily trusted by con-
sumers as those from public health, when available [31]. The
response of industry to RUVs has been slow, for lack of any tra-
dition of direct-to-consumer advertising and federal restrictions
on this activity. However, recent television and print ads for zoster
and HPV vaccines have been artful and presumably effective.
Other  important but less obvious measures to support private
vaccine sales included ensuring the availability of approved prod-
uct within Canada, providing single dose vials, facilitating small
shipments of vaccine to local distributors and pharmacies, and
accepting return of outdated product. Setting a fair price is also
conducive to private sales.
2.6. Better approaches to RUV use
Recent history suggests that the RUV phenomenon will con-
tinue, with delayed funding of some new vaccines, limited funding
of others, and non-funding of still other vaccines. Canadians will
either have to forgo the individual protection offered by these vac-
cines or new means will need to be found to encourage greater
use.
The preferred strategy is obviously to minimize RUV situa-
tions. Better coordination of decision-making among stakeholders
regarding the use of new vaccines could help to narrow the gap
between marketing approval and funded use and to avoid glar-
ing discrepancies among provincial programs. The ideal would
be a single, fully integrated Canadian NITAG in which all fund-
ing stakeholders (provincial, territorial, federal) participate, with a
commitment to promptly implement programs with selected prod-
ucts. An offer of substantial initial federal funding to aid concurrent
implementation of programs in all jurisdictions might suitably
reward such collective decision-making. Federal funds made avail-
able for the ﬁrst time as part of a new national immunization
strategy in 2005 [32,33] successfully launched programs in all
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rovinces with pneumococcal and meningococcal C conjugates,
cellular pertussis vaccine for adolescents, and varicella and, in
009, with HPV vaccines [34]. This approach ought to be continued,
s immunization programs should be uniform across the country
26]. The goal for Canada is already the norm in the USA, where
 central NITAG (ACIP) determines national recommendations and
riggers federal funding to provide access by low income families
Vaccines for Children program), state programs and expectations
f matching coverage by health insurance programs.
Realistically, governments will not be able to fund every vac-
ine that offers potential beneﬁts. Public immunization programs
re tailored to beneﬁt those most at risk rather than all who are at
isk. However, individuals should have an option to obtain protec-
ion or enhance it if they wish to take advantage of an available,
nfunded vaccine. This will become increasingly important as per-
onalized vaccinology [35] advances: what works for most may  not
e optimal for some, who would be better served by a non-standard,
ossibly unfunded, vaccine.
To create conditions more favorable to using RUVs, a number of
hanges are needed, as described below.
. Increasing public awareness and education
CMPA [21] was prescient a decade ago in recognizing that indi-
iduals should be made aware of their options to prevent infections
hrough vaccination, whether the particular vaccines of poten-
ial beneﬁt to them are publicly funded or not. This obligation
hould apply to all professionals who administer vaccines. How-
ver, the burden for informing the public should not fall on vaccine
roviders alone. Vaccine information pamphlets and web summ-
ries produced by professional organizations are very useful for
ublic education, given that individuals typically have most trust
n their physician and related professional organizations [31]. It
ould be helpful for more professional organizations to assist with
he educational challenges of RUVs, with alliances such as Immu-
ize Canada [28] providing a convenient vehicle. Advocacy should
lso include public health at every level, which should position
tself as supporting all recommended vaccines, whether funded
r not. Acknowledging limitations in public funding might attract
riticism of government decisions but will also foster healthy
ebate about the scope of vaccine provision. To encourage RUV
se, health departments should provide the same types of informa-
ion (such as website entries) to immunizers and the public as they
o for funded vaccines. Consumer organizations such as the Cana-
ian Association of Retired Persons (CARP) could provide valuable
dvocacy and education among their peer groups for relevant vac-
ines [36]. With greater mobilization, large organizations like CARP
ight inﬂuence funding decisions for vaccines [36,37] like zoster,
he cost-effectiveness of which has been repeatedly demonstrated
38,39].
Clearly, RUVs will always be at a great disadvantage compared
ith publicly-funded vaccines in terms of public acceptance. They
ay  also be more vulnerable to public complacency and anti-
accination sentiments. A key countermeasure will be common
essaging among the advocates for RUV use, emphasizing the
alue of these “optional” immunizations for individuals at risk.
.  Reducing ﬁnancial barriers for RUV purchase
Current RUVs are expensive, putting them beyond the means
f many who are most vulnerable. In Canada, medication costs for
ow-income households are covered by provincial drug plans. At
resent, such plans do not cover vaccines but there is no logical
eason to exclude RUVs for eligible individuals. Eligibility should
lso include individuals who will be better served by unfundede 32 (2014) 766– 770 769
alternative vaccines (e.g. a non-egg derived inﬂuenza vaccine, for
someone with hypersensitivity to egg). Drug plans currently pay
for preventive medications such as cholesterol-lowering agents,
at far greater costs per person ($313–$1,428 per year in a recent
US survey) [40] than are involved for vaccines and with much
less evidence of beneﬁt. For employed persons, a minority of
supplemental health insurance plans cover unfunded vaccines and
more could do so with sufﬁcient demand from policy holders. Fair
pricing will be important for all consumers; rebates for low-income
consumers should be offered by companies as they do for some
drugs. Some vaccine companies have developed “access programs”
offering discounted prices of certain new vaccines [41], a com-
mendable measure worth expanding. Fees charged by pharmacists
to administer a RUV pose another barrier to consumers [41] and
would be better assigned to healthcare insurance plans given the
potential beneﬁts of the intervention. Another solution would be
federal funding directed at low-income consumers, analogous to
the Vaccines for Children program in the USA that follows the
recommendations of the national NITAG (ACIP).
Economic analyses are creating a further barrier to the adoption
of some approved vaccines [42,43]. The costs and beneﬁts of new
vaccines are rigorously evaluated in a way  that many other types of
healthcare products and procedures are not [44]. If a bar is to be set
for vaccines, it should not be higher than that applied to other parts
of healthcare, and decisions to fund or not should be taken in the
full context of the breadth of healthcare spending. This requires a
more rigorous approach to healthcare spending decisions in other
sectors of the industry.
5.  Changing public perceptions about RUVs
A ﬁnal barrier to use of RUVs is the widely-held perception
among Canadians that if a vaccine will beneﬁt them individually
it will be provided to them at no cost. This reluctance to pay for
vaccines is rooted in history but stands in sharp contrast to many
other recommended personal preventive measures that Canadi-
ans must pay for such as statin drugs, infant car seats, sunscreens,
and bicycle helmets. Studies to examine attitudes of health pro-
fessionals and the public about purchasing vaccines and how to
modify them are urgently needed. Central to success will be a bet-
ter understanding of what motivates individuals to accept a vaccine
[45,46] and how best to market vaccines to individual consumers.
The public is increasingly health conscious and heeds other user-
pay prevention advice. Optimal roles of public health, professional
organizations/collaborations and the vaccine industry in educat-
ing the public need to be clariﬁed, including the role and ethics of
direct-to-consumer advertising by any of these stakeholders.
The  greatest need is to change the widespread perception that
vaccines should be publicly funded or ignored. The long-standing
and total dominance of population over individual considerations
for vaccines needs to end or the potential beneﬁts of some vaccines
will not be realized, to the detriment of those at risk. It is a form of
discrimination against vaccines compared with (preventive) drugs
that urgently needs to be corrected.
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